Korean turmeric is effective for dyslipidemia in human intervention study  by Kim, Jin Hee et al.
lists available at ScienceDirect
J Ethn Foods 3 (2016) 213e221ContentsJournal of Ethnic Foods
journal homepage: http: / / journalofethnicfoods.netOriginal articleKorean turmeric is effective for dyslipidemia in human intervention
study
Jin Hee Kim a, Hye Jeong Yang a, Yong-Jae Kim b, Sunmin Park c, Ok-hee Lee d,
Kang Sung Kim d, *, Min Jung Kim a, *
a Korea Food Research Institute, Sungnam, Republic of Korea
b Korea INS Pharmaceutical Co., Jeollanam-do, Republic of Korea
c Department of Food Science & Nutrition, Hoseo University, Asan, Republic of Korea
d Department of Food Science & Nutrition, Yongin University, Yongin, Republic of Koreaa r t i c l e i n f o
Article history:
Received 8 July 2016
Received in revised form
26 July 2016
Accepted 6 August 2016
Available online 7 September 2016
Keywords:
liver function
mass spectrophotometer
metabolites
turmeric powder* Corresponding authors. Kang Sung Kim, Depar
Nutrition, Yongin University, 470 Samga-dong Cheoi
Korea; Min Jung Kim, Korea Food Research Ins
1201-bunkil, Songnam, 463-746, South Korea.
E-mail address: kss@yongin.aco.kr (K.S. Kim).
http://dx.doi.org/10.1016/j.jef.2016.08.006
2352-6181/© 2016 Korea Food Research Institute. Pu
licenses/by-nc-nd/4.0/).a b s t r a c t
Background: Turmeric is a plant that belongs to the ginger family, Zingiberaceae, and is one of the main
ingredients in curry powder. Turmeric is often called the golden spice and has been used for medicinal
purposes for thousands of years. Curcumin, which gives turmeric its yellow color, has been conﬁrmed to
have antioxidant, anti-inﬂammatory, and anti-infectious effects. It is also known to prevent dementia
and promote liver health. For these reasons, turmeric is regarded as a therapeutic food additive with
many health beneﬁts beyond its nutritional value. In this paper, the health beneﬁts of turmeric were
examined through human intervention studies.
Methods: Thirty chosen individuals (28 men and 2 women) with slightly elevated alanine amino-
transaminase levels consumed 1 g of turmeric powder (TP) as two capsules after each meal, three times a
day, during the test period of 12 weeks. Changes in the lipid proﬁle and in the levels of serum glucose,
malondialdehyde, and metabolites in the sera were measured prior to and after TP consumption.
Results: The participants exhibited dyslipidemia, fasting hyperglycemia, and oxidative stress prior to TP
treatment, and these symptoms were alleviated after treatment. On metabolomics analysis of sera, levels
of branch-chained amino acids (valine and leucine/isoleucine) were decreased, whereas those of aro-
matic amino acids (tryptophan and phenylalanine) were increased. Pronounced changes were also noted
in the levels of total lysophosphatidylcholine (lysoPC) and acylcarnitine: the levels of total lysoPC were
decreased whereas those of acylcarnitine were increased. Serum levels of xanthine and hypoxanthine,
which are intermediates of purine degradation, were increased in the participants, although that of the
ﬁnal product, uric acid, was decreased.
Conclusion: Oral consumption of TP alleviated dyslipidemia and changed metabolites patterns by
accelerating metabolic activities with less oxidative stress in participants with mild liver dysfunction.
© 2016 Korea Food Research Institute. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Turmeric (Curcuma longa L.; Fig. 1) is a perennial herbaceous
plant species belonging to the family Zingiberaceae, known to have
originated in India. Currently, it is grown in Korea, Japan, Taiwan,
and Indonesia, along with other countries. The oldest writtentment of Food Science and
nGu, Yongin, 449-714, South
titute, 62 Anyangpankyo-ro
blished by Elsevier B.V. This is anrecord of turmeric dates back to B.C. and indicates that it was used
as a food additive (spice), food preservative, and food coloring.
In India, turmeric is called haldi [1] and has been traditionally
used as a dyeing agent for clothes due to its yellow color [2e3].
Turmeric has also been used in important ceremonies and rituals,
such as weddings, by applying turmeric paste on the body or by
tossing rice mixed with turmeric power towards the bride and
groom [4e6]. Leprosy, chicken pox, and skin ulcers have been
treated with ointments made from turmeric and by bathing in
water with turmeric [7,8]. In the Ayurveda, the ﬁrst Indian publi-
cation on medicine, turmeric is described as a common anti-
inﬂammatory agent [9]. Additionally, turmeric has been used inopen access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Roots of turmeric and their powder.
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frommuscle sprain or injury, bilious attack, loss of appetite, rhinitis,
colds, diabetic wounds, liver disease, rheumatism, and sinus
infection [1,10].
Turmeric powder has been shown to play an important role in
increasing nutritional value, prolonging freshness, and preserving
the quality, preferability, and integrity of shape [11,12]. Because of
these characteristics, turmeric became one of the major ingredients
in curry, a staple and famous dish in Indian cuisine.
China and many Southeast Asian countries have used turmeric
to dye clothes, color food, and brew alcoholic drinks [11]. In Japan,
turmeric (or Ukon in Japanese) has been widely enjoyed as a tea
and medicinal herb [3,13]. A written record of the cultivation and
therapeutic use of turmeric in Korea is found in the Sallimkyungje
(山林經濟), a comprehensive book on households published during
the late reign of the Chosun Dynasty (Fig. 2) [14]: Turmeric can only
be grown in certain areas. Fine turmeric has a shape that resembles
the stomach of a cicada. Its fragrance is mild and the qi (氣) is light
and fast (揚)… (在處有之形如蟬肚者佳此物不甚香但其氣輕揚能致
達酒氣於高遠 以降神也). This record indicates a long history of
farming and medicinal use of turmeric in Korea. As to where
turmeric was grown, the Sejongsillokjiriji (世宗實錄地理志) [15]
mentioned that turmeric was cultivated in the towns of Gurye,Fig. 2. Turmeric was recorded in Sallimkyungje (山林經濟) written by the Hong Man-
Seon (洪萬選) in the late 17th century. The ancient documents are provided by the
Jangseogak Archives at the Academy of Korean Studies.Nakan, and Suncheon in the Jeonla-do province, whereas the
Sinjeung-dongguk-yeoji-seungram (新增東國輿地勝覽) (Fig. 3) [16]
stated that turmeric was a native product grown in Dongbok
(Hwasun), Gwangyang, Goksung, Imsil, Sunchang, and Jeonju, and
also in Jeonla-do. Currently, the town of Jindo in the Jeonlanam-do
province is responsible for the mass cultivation of turmeric, using a
system of geographical indications, and this continues to expand
[17,18].
According to the Korean medical encyclopedia called Dongui-
bogam (東醫寶鑑) (Fig. 4), translated literally as Principles and
Practice of Eastern Medicine and ﬁrst published in 1610, during the
reign of the Chosun Dynasty, turmeric is described as being both
cold (or soothing) and hot (or causing body temperature increase)
while being nontoxic; C. longa L. was used to treat a mass caused by
stagnant blood, decrease qi (氣) ﬂow, stop a nosebleed, and elimi-
nate blood stasis [19]. The medical book claims that turmeric can
help relieve blood extravasation, as well as alleviate qi (overﬂow of
energy), both of which are thought to be harmful. It also recom-
mends the rhizome as antidotes for hematuria and anxiety. This
indicates that turmeric has been traditionally used for improving
health in Korea.
1.1. Effects of curcumin
Turmeric is rich in phenolic curcuminoids such as curcumin,
demethoxycurcumin, and bisdemethoxycurcumin [20,21]. It is
known to have antioxidant, anti-inﬂammatory, and anti-infectious
activities [7,20,21]. Animal and human studies with turmeric have
revealed the versatility of the rhizome both as a prophylactic agent
and a cure for many ailments as well as a hepatoprotective agent for
the alleviation of obesity [20,21]. Turmeric has been shown to be an
effective therapeutic agent against arthritis, ischemic stroke, dys-
lipidemia, nonalcoholic steatohepatitis, and atherosclerosis in
many experimental animal studies [22]. In addition, curcuminoids
have been demonstrated to improve insulin sensitivity by sup-
pressing adipogenesis, reducing elevated blood pressure, and
mitigating inﬂammation and oxidative stress. Curcumin, one of the
major curcuminoids in turmeric, is an inhibitor of cyclooxygenase-2
expression, which is involved in inﬂammation [23]. The efﬁcacy of
turmeric has been evaluated in limited randomized controlled
clinical trials. Panahi et al [24] reported that curcuminoids plus
piperine effectively reduce serum levels of low-density lipoprotein
cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), and
lipoprotein A, and elevate high-density lipoprotein cholesterol
(HDL-C) levels in patients with metabolic syndrome. As dyslipide-
mia results in the deposition of fatty streaks in the blood vessels
when pro-oxidants damage the vessels, dyslipidemia is associated
with arthrosclerosis [25]. Turmeric can prevent arthrosclerosis by
improving dyslipidemia and antioxidant capacity. In addition,
fermentation changes the form of bioactive components that
generally increase the activity by removing glycosides of the
components [26].
The health beneﬁts of turmeric cited by many sources were
garnered through a human intervention study using turmeric
produced from Jindo, a southern region in Korea. During the 12-
week test period, improved dyslipidemia was observed in partici-
pants after consuming turmeric.
2. Materials and methods
2.1. Ethics approval and study design
This study was approved by the Functional Foods Institutional
Review Board of Chonbuk National University Hospital (CUH IRB
2010-02-17), Jeonju, South Korea. Between November 2010 and
Fig. 3. Turmeric was a local food product in Korea, which was reported in the Sinjeung-dongguk-yeoji-seungram (新增東國輿地勝覽), written by Lee Haeng ( 荇) et al in 1530. The
ancient documents are provided by the Kyujanggak Institute For Korean Studies.
Fig. 4. The efﬁcacy of turmeric was described in Donguibogam (東醫寶鑑), written by Heo Jun (許浚) in 1610. The ancient documents were provided from the Jangseogak Archives at
the Academy of Korean Studies.
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evaluate the metabolic alterations in test individuals who
consumed TP. All participants lived in the city of Jeonju, Cholla
Province, South Korea. As part of the initial workup, the partici-
pants who signed up for the test underwent hepatic ultrasonog-
raphy and typical liver function tests [e.g., tests to measure levels of
enzymes such as alanine aminotransaminase (ALT), aspartate
aminotransferase (AST), and gamma-glutamyl transferase]. The
other biochemical indices determined were TC, TG, HDL-C, and
LDL-C levels. Thirty participants with ALT levels between 40 IU/L
and 200 IU/L, which were slightly above the normal range of
10e40 IU/L, were chosen as the test participants. The exclusion
criteria were as follows: positive serology results for hepatitis B
virus and hepatitis C virus, abnormal transferrin saturation,
decompensated cirrhosis, and pregnancy. After none of the patientswere excluded, all participants were asked to provide written
consent prior to the start of the study. The participants were asked
to take 3.0 g/d of powdered turmeric for 12 weeks, i.e., six capsules
of turmeric per day, which corresponds to two capsules after each
meal. As this study was a part of a randomized double-blinded
clinical trial, the participants were not informed about what they
were consuming. The participants were asked to maintain their
everyday lifestyle, such as eating habits, exercise, and alcohol
consumption [27].
2.2. TP capsule preparation
The dried turmeric powder was capsulated with 500 mg in each
capsule. The TP capsules were kindly provided by Korea INS Phar-
maceuticals, Inc. (Hwasoon, Jeonnam, South Korea). The curcumin
Table 1
Effects of consuming TP on triglyceride, total cholesterol, HDL-cholesterol, glucose,
and malondialdehyde levels of test participants.*
0 wk 12 wk p
TG (mg/dL)y 198.38 ± 88.1 162.95 ± 71.0 0.189
T-chol (mg/dL) 258.38 ± 25.2 241.52 ± 26.3 0.077
HDL-chol (mg/dL) 27.44 ± 6.3 29.98 ± 8.03 0.187
Glucose (mg/dL) 130.75 ± 20.5 110.96 ± 15.0 0.017
Malondialdehyde (mM) 1.82 ± 1.99 0.80 ± 0.69 0.019
* Mean ± standard error of the mean.
y Tested by long transformed.
BMI, body mass index; HDL-chol, high-density lipoprotein cholesterol; T-chol, total
cholesterol; TCI, total calorie intake; TFE, total energy expenditure; TG, triglyceride.
J Ethn Foods 2016; 3: 213e221216content of the TP was tested using high-performance liquid chro-
matography at the Korea Health Supplement Institute (Jeonju,
Jeollabuk-do, South Korea) and was found to be approximately
0.79 mg/g [27].
2.3. Biochemical analysis
All serum samples were kept frozen at e70C until they were
assayed. Serum glucose levels were measured using an enzymatic
colorimetric method with a commercial enzymatic assay kit (Asan
Pharmaceutical Co., Seoul, Korea). The TC, TG, HDL-C, and LDL-C
levels in serum were measured according to the manufacturer's
instructions (Asan Pharmaceutical Co., Seoul, Korea). All analyses
were measured using a UV spectrometer (JASCO, Tokyo, Japan).
Serum malondialdehyde (MDA) levels were determined using the
thiobarbituric acid reactive substances method with commercial
kits (Cell Biolabs, San Diego, CA, USA). Glutathione levels in serum
were measured using the Glutathione Assay Kit (Cayman, Ann Ar-
bor, MI, USA) according to the manufacturer's instructions.
2.4. Serum analysis by ultraperformance liquid chromatography-
quadrupole-time of ﬂight-mass spectrometry
We collected 150 mL of sera from the 30 participants at the
beginning and the end of the study, to which 300 mL of cold
acetonitrile was added to extract soluble metabolites. After shaking
for 30 minutes at 4C, the samples were centrifuged at 5,590 g for
10 minutes, at 4C. The supernatants were freeze-dried and stored
at 70C, and were subsequently dissolved in 20% methanol just
prior to the ultraperformance liquid chromatography-quadrupole-
time of ﬂight-mass spectrometry (UPLC-Q-TOF-MS) analysis [28].
Serum extracts were analyzed on a UPLC-Q-TOF-MS instrument
(Waters, Milford, MA, USA), as described in our previous report
[28]. The Q-TOF-MS was operated in positive electrospray ioniza-
tion (ESI) mode, with a scan range of m/z 50e1,000. The cone
voltage was 30 V, the capillary voltage was 3 kV, and the scan time
was 0.2 second, with an interscan delay of 0.02 second. The source
temperature was set at 110C, and the desolvation ﬂow rate was set
at 700 L/h. The desolvation gas temperaturewas 300C. TheMSwas
calibrated using sodium formate, and leucine enkephalin was used
as lock mass. The concentration of leucine enkephalin was 200pM,
and the ﬂow rate was set at 5 mL/min. As quality control, a mixture
of ﬁve standard compounds (4-acetoaminophenol, caffeine, sulfa-
dimethoxine, terfenadine, and reserpine) was injected after
running every eight samples.
In the MSeMS experiments, argon was used as collision gas,
with the collision energy alternating between 10 eV and 30 eV. The
MassLynx software version 4.1 (Waters Inc.) was used to control the
instrument and calculate accurate masses. Peaks were collected
using a peak width at 5% height, 1 second, a noise elimination of 6,
and an intensity threshold of 70. Data were aligned with a mass
tolerance of 0.04 Da and a retention time window of 0.2 minute. All
spectra were aligned and normalized to an external standard.
Assignment of metabolites contributing to the observed variance
was performed using the ChemSpider [29] and Human Metab-
olome Database [30].
2.5. Data processing for statistical analyses
Statistical analyses were performed on the data using the
SIMCA-Pþ software (ver. 12.0.1; Umetrics Inc., Umeå, Sweden).
Partial least-squares discriminant analysis (PLS-DA) was used to
visualize discrimination among samples, and an internal sevenfold
cross-validationwas carried out to estimate the performance of the
PLS-DA models. Goodness of ﬁt was quantiﬁed by R2X and R2Y, andthe predictive ability was indicated by Q2Y. In addition to cross-
validation, model validation was also performed by a 200-times
permutation test. Analysis of variance was performed to deter-
mine the statistical signiﬁcance using SPSS 11.5 (SPSS Inc., Chicago,
IL, USA) at a signiﬁcance level of p < 0.05 [28].3. Results and discussion
3.1. Lipid proﬁles of participants
The liver plays an important role in lipid metabolism. Liver
damage is caused by various factors such as alcohol, virus infection,
and toxic compounds that increase inﬂammation and oxidative
stress by damaging the hepatocytes. The damage possibly results in
dyslipidemia and the accumulation of lipids, leading to nonalco-
holic fatty liver disease. Thus, the alleviation of liver damage by
herbs with anti-inﬂammation, antioxidant, and antiviral activities
can also improve dyslipidemia.
The mean age of the eligible individuals was 39.0±8.5 years,
and the mean body mass index was 26.8±3.3 kg/m2. The mean
body mass index of the participants remained virtually unchanged
until the end of the study.
Prior to consuming TP, the participants had dyslipidemia; the
serum TG, TC, and HDL-C levels were 198.4 ± 88.1 mg/dL,
258.4 ±25.2 mg/dL, and 27.4 ± 6.3 mg/dL, respectively (Table 1). TP
consumption for 12 weeks signiﬁcantly lowered serum TG, TC, and
glucose levels, and increased serum HDL-C levels in comparison to
the levels prior to consumption. In addition, fasting serum glucose
levels decreased from 130.8 ± 20.5 to 111.0 ±15.0 mg/dL after TP
treatment (Table 1). TP treatment alleviated dyslipidemia and hy-
perglycemia in humans with abnormal liver function.
In the present study, LDL-C oxidation was not determined, but
serum MDA levels, an indicator of oxidative stress, decreased from
1.82 ± 1.99 mM to 0.80 ± 0.69mM after TP treatment for 12 weeks.
Thus, TP reduced oxidative stress.3.2. Serum metabolic proﬁles
The sera from the 30 participants collected at 0 week and 12
weeks after TP were analyzed using UPLC-Q-TOF-MS. The resulting
chromatograms obtained in positive ion (ESIþ) mode are shown in
Fig. 5. The data thus obtained were used for preparing a PLS-DA
score plot to elucidate the existence of class distinction between
the samples (Fig. 6A). The PLS-DA score plot showed a separation
between 0-week and 12-week serum samples along the axes that
correspond to the ﬁrst two PLS-DA components. The variation in X
(R2X) and Y (R2Y) was 30.7% and 70.6%, respectively, with the pre-
diction percentage of the variation in response Y (Q2Y) for the two-
component model being 34.9%. The R2 intercept value, evaluated
using the permutation test, was 0.349 and the Q2 intercept value
was 0.159. Thus, the sera of participants at 0 week and 12 weeks
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Fig. 5. High performance liquid chromatography-quadrupole-time of ﬂight-mass spectrometry (UPLC-Q-TOF-MS) proﬁles of sera from human participants who were controlled by
TP prior to and after 12 weeks of intervention.
–
–
–
–
–0.2–2.0
R2X 0.327, R2Y = 0.673, Q2Y = 0.350, p = 0.002
R intercept = 0.302, Q intercept = –0.185
A B
Fig. 6. Partial least-squares discriminant analysis (PLS-DA) score plot and S-plot. (A) PLS-DA scores plot obtained from the mass spectrometry data of the sera from study par-
ticipants. Clear discrimination between the participants at Week 0 (open circle) and at Week 12 (ﬁlled circle) was obtained. (B) S-plot covariance [p] and reliability correlation [pcorr]
from PLS-DA models. The numbers for the metabolites are as given in Table 2.
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ponents with the goodness of ﬁt of the data. These results clearly
indicate that the participants who consumed TP for 12 weeks
experienced changes in the proﬁles of the serum metabolites.
The contribution of analyzed metabolites in the separation of
sera of the 30 participants at 0 week and 12 weeks was determined
by drawing the S-plot along the axes corresponding to the com-
bined weight and reliability correlation (pcorr) (Fig. 6B). A higher or
lower value of pcorr was associated with the greater degree of
contribution made by these metabolites to the separation of the
test samples. Positive pcorr values correspond to those with
decreased serum levels due to TP consumption, whereas metabo-
lites with negative values correspond to increased levels during thestudy period. All the 33metabolites detected were marked in the S-
plot, with the ones stipulated with numbers as the metabolites that
were identiﬁed using MSeMS. Variable importance in the projec-
tion scores (VIP scores) and the normalized fold changes of the
metabolites due to TP consumption are presented in Table 2. The 13
metabolites that showed signiﬁcant increases in levels during TP
treatment were xanthine (p ¼ 0.004), phenylalanine (p ¼ 0.02),
palmitoleic acid (p ¼ 0.000), palmitylcarnitine (p ¼ 0.000), stear-
oylcarnitine (p ¼ 0.003), palmitic acid (p ¼ 0.005), acetylcarnitine
(p ¼ 0.007), argininosuccinic acid (p ¼ 0.048), hypoxanthine
(p ¼ 0.031), butyrylcarnitine (p ¼ 0.047), decanoylcarnitine
(p ¼ 0.014), methylmalonylcarnitine (p ¼ 0.019), and LPC (C22:6)
(p ¼ 0.042). Six metabolitesdvaline (p ¼ 0.02), lysine (p ¼ 0.04),
Table 2
Identiﬁcation of serum metabolites of study participants (non-TP and TP) analyzed
using UPLC-Q-TOF-MS.
No. Identity Exact
mass
Actual
mass
Mass
error
p VIP
(M þ H) (M þ H) (mDa)
1 Valine 118.0868 118.0841 2.7 0.020 1.7
2 Benzoic acid 123.0434 123.0418 1.6 0.010 2.13
3 Leucine/isoleucine 132.1025 132.1006 1.9 0.040 1.8
4 Homocysteine 136.0432 136.0725 29.3 0.200 2.0
5 Hypoxanthine 137.0463 137.0443 2 0.031 1.31
6 Lysine 147.0770 147.0426 34.4 0.004 1.79
7 Xanthine 153.0413 153.0642 22.9 0.001 2.06
8 L-Carnitine 162.1130 162.1098 3.2 0.276 1.0
9 Phenylalanine 166.0868 166.0817 5.1 0.02 1.1
10 Uric acid 169.0362 169.0321 4.1 0.057 2.67
11 Acetylcarnitine 204.1025 204.1357 33.2 0.007 0.64
12 Tryptophan 205.0977 205.0934 4.3 0.413 1.41
13 Butyrylcarnitine 232.1549 232.1544 0.5 0.047 0.8
14 C16:1 (palmitoleic acid) 255.1457 255.1579 12.2 0.000 1.05
15 C16:0 (palmitic acid) 257.1810 257.1723 8.7 0.005 1.23
16 Methylmalonylcarnitine 262.1291 262.1506 21.5 0.019 0.71
17 Octanoyl carnitine 288.2170 288.2482 30.7 0.003 1.24
18 Argininosuccinic acid 291.1305 291.1369 6.4 0.048 0.46
19 Decanoylcarnitine 316.2488 316.2421 6.7 0.014 2.45
20 Palmitylcarnitine 400.3427 400.3404 2.3 0.000 2.42
21 Stearoylcarnitine 428.3740 428.3739 0.1 0.003 1.20
22 LysoPC (C14:0) 468.3090 468.3047 4.3 0.100 1.4
23 LysoPE (C18:2) 478.2934 478.3248 31.4 0.200 1.3
24 LysoPC (P16:0) 480.3454 480.3425 2.9 0.205 1.3
25 LysoPE (C18:0) 482.3168 482.3232 6.4 0.081 1.2
26 LysoPC (C16:0) 496.3403 496.3337 6.6 0.050 5.9
27 LysoPE (C20:4) 502.2934 502.3294 36 0.007 1.68
28 LysoPC (C18:3) 518.3247 518.3252 0.5 0.177 1.1
29 LysoPC (C18:2) 520.3403 520.3266 13.7 0.070 4.0
30 LysoPC (C18:1) 522.3560 522.3422 13.8 0.200 3.2
31 LysoPC (C18:0) 524.3716 524.3588 12.8 0.244 4.6
32 LysoPC (C20:4) 544.3403 544.3331 7.2 0.060 1.5
33 LysoPC (C22:6) 568.3403 568.3341 7.2 0.042 1.4
lysoPC, lysophosphatidylcholine; lysoPE, lysophosphatidylethanolamine; UPLC-Q-
TOF-MS, ultraperformance liquid chromatography-quadrupole-time of ﬂight-mass
spectrometry; VIP, variable importance in the projection scores.
J Ethn Foods 2016; 3: 213e221218benzoic acid (p ¼ 0.01), leucine/isoleucine (p ¼ 0.04), octa-
noylcarnitine (p¼ 0.003), and lysophosphatidylethanolamine (LPE)
(C20:4) (p ¼ 0.007)dwere found to decrease during the same
period. Uric acid (p ¼ 0.06) and lysophosphatidylcholines (lysoPCs)
containing C18:2 (p ¼ 0.07), C16:0 (p ¼ 0.06), and C20:4 (p ¼ 0.06)
showed insigniﬁcant variations, with fold changes in the range of
0.8e1.2 (Fig. 7). Palmitoleic acid, xanthine, palmitoylcarnitine,
leucine/isoleucine, octanoylcarnitine, and LPE (C20:4) exhibited the
highest changes in levels, with VIP values being >3.0. In particular,
palmitoleic acid, xanthine, LPE (C20:4), and octanoylcarnitine were
determined to be the most important parameters for discrimi-
nating samples.
The correlations between these major metabolites to some
biochemical markers, such as MDA and HDL-C, were accessed using
the Pearson correlation test (Fig. 8). Among the major metabolites
with VIP values >3.0, the levels of xanthine and octanoylcarnitine
were found to be reversely proportional to those of MDA and HDL-C
levels, suggesting that TP was able to accelerate lipid catabolism
without promoting oxidative stress, where both lipolysis and
reactive oxygen species synthesis were facilitated.
3.3. Dyslipidemia
This study demonstrated that TP treatment for 12 weeks alle-
viated the metabolic disorders of the individuals with slightly
elevated AST and ALT activities who had dyslipidemia, higher
fasting hyperglycemia, and oxidative stress. In addition, in themetabolomics analysis of sera, levels of branch-chained amino acid
(BCAA), such as valine and leucine/isoleucine, were decreased,
whereas those of aromatic amino acids, such as tryptophan and
phenylalanine, were increased. Total lysoPCs were reduced and
acylcarnitine levels were increased in the circulation. Serum levels
of xanthine and hypoxanthine, which are intermediates of purine
degradation, were increased in the participants, although that of
the ﬁnal product, uric acid, was decreased. TP modulates fatty acid
transport from the cytosol to the mitochondria for b-oxidation and
amino acid and purine degradation in the circulation. The param-
eters that were changed on metabolomics analysis in the present
study (i.e., BCAA, acylcarnitines, and phospholipids) have been
identiﬁed as potential biomarkers for obesity, and the results
indicated that they are also involved in lipid metabolism in the liver
[31]. Thus, TP might improve lipid metabolism in the liver in par-
ticipants with moderate liver damage.
Similar to unfermented turmeric, TP ameliorated dyslipidemia
and oxidative stress, thereby decreasing the risk of atherosclerosis.
Turmeric and its major polyphenol (curcumin) have been reported
to have prevented and improved dyslipidemia and oxidative stress.
Ejaz et al [32] and Weisberg et al [33] claimed that consuming
curcumin may help alleviate metabolic disorders associated with
obesity by suppressing adipose tissue angiogenesis as well as by
increasing energy metabolic process of adipocytes. However, only a
few studies have been conducted to determine the effects of TP on
dyslipidemia, even though fermentation has been claimed to
improve the bioactivity by removing glycosides attached to poly-
phenols in various herbs. TP administration (200 mg/kg and
500 mg/kg of body weight) resulted in alleviation of dyslipidemia
in ob/ob mice; the TC and TG levels in the serum and liver signif-
icantly decreased compared to that observed after placebo
administration, and HDL-C levels signiﬁcantly increased [34]. In
addition, TP also reduces lipid peroxidation and hepatotoxicity in
rats with CCl4-induced liver diseases by enhancing the antioxidant
capacity owing to increase in the activities of antioxidant enzymes
such as catalase, glutathione-S-transferase, glutathione reductase,
and glutathione peroxidase [22]. These results suggest that TP may
improve dyslipidemia by ameliorating liver damage via the
reduction of oxidative stress and the restoration of liver function-
enhanced lipid metabolism.
3.4. Carnitine/acylcarnitine levels
L-Carnitine is mainly absorbed from the diet, but is also formed
through biosynthesis in the human liver, kidneys, and brain. Other
tissues receive L-carnitine from circulation [35]. L-Carnitine is a
form of acylcarnitine that acts as the transporter of fatty acids into
the mitochondria from the cytosol. Acylcarnitine is transferred into
the mitochondria and changed into fatty acid, thereby producing
energy. Carnitine also plays an important role in fatty acid transport
from peroxisomes, where long-chain fatty acids are partially
degraded [22]. L-Carnitine is important for utilizing fatty acids. The
acylcarnitine proﬁle is directly inﬂuenced by diet and metabolic
status such as fasting [35]. Acylcarnitine is a product of incomplete
fatty acid oxidation, and it is associatedwith the altered ﬂux of fatty
acid oxidation [36,37]. Although acylcarnitine is reported to in-
crease during fasting and possibly in an insulin-resistant state, the
ﬁndings are still controversial. Moreover, there are no correlations
between acylcarnitine in the tissue and serum [35]. Serum acyl-
carnitine levels may not reﬂect the insulin-resistant state. In the
present study, TP consumption led to increasing the ratio of acyl-
carnitines and carnitine by 1.55-fold in the serum as compared to
that observed prior to TP consumption. The correlation study
demonstrated that the serum levels of MDA were positively asso-
ciated with those of octanoylcarnitine. These results suggested that
Fig. 7. The fold changes of serum metabolites in participants at 12 weeks were calculated against those at 0 week and are presented as positive and negative values. LPC, lyso-
phosphatidylcholine; LPE, lysophophatidylethanolamine.
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acylcarnitine, may be associated with increasing oxidative stress
and insulin resistance. Ejaz et al [32] demonstrated that curcumin-
fed mice exhibited increased expression of CAP1 as well as
decreased expression of PPAR-g (peroxisome proliferator-activated
receptor gamma) and CCAAT/enhancer binding protein-a, which
might lead to an increase in b-oxidation and decrease in fatty acid
synthesis. Thus, the elevation of serum acylcarnitine levels in the
present study may be associated with the increase of fatty acid
oxidation in a fasting state after TP consumption.
3.5. LysoPC levels
LysoPC and lysophosphatidylethanolamine (lysoPE) are pro-
duced as the intermediates during the formation or breakdown of
phosphatidylcholines and phosphatidylethanolamines, respec-
tively. LysoPC and lysoPE are closely associated with certain disor-
ders such as endothelial dysfunction, inﬂammation, and obesity
[38e40]. The levels of both total lysoPC and lysoPE were
decreased by approximately 20% in the sera of the participants after
TP consumption. In the present study, the serum levels of lysoPCs
18:1, 18:2, 18:0, and LPE 20:4 were decreased, whereas that of
lysoPCs 22:6, 20:4, 14:0, 16:0, 18:3, and LPE 18:2 were slightly
increased, in ascending order. Similar to the results of our study,
studies on obese men [41] and monozygotic twins [42] revealed
that the plasma lysoPC level is associated with obesity. Moreover,
other studies showed that these hydrolyzed phospholipid levelsand obesity were unrelated, and thus, further studies with human
volunteers are necessary to fully ascertain the role of these com-
pounds in obesity [43]. Thus, TP improved lipid metabolism
considering lysoPC and lysoPE levels in circulation.
3.6. Serum BCAA levels
Circulating levels of BCAAs tend to increase in individuals with
obesity, insulin resistance, or type 2 diabetes mellitus [43]. This
may be related to increased insulin resistance. Insulin resistance
might promote aminoacidemia by increasing the protein degra-
dation that insulin normally suppresses, and/or by eliciting an
impairment of efﬁcient BCAA oxidative metabolism in some tis-
sues [44,45]. The accumulation of mitotoxic metabolites, possibly
BCAA, promotes b-cell mitochondrial dysfunction, stress
signaling, and apoptosis associated with type 2 diabetes [46]. The
metabolism of BCAAs is also affected in other diseases associated
with insulin resistance, including kidney and liver dysfunction
[46]. The present study demonstrated that the levels of BCAAs,
notably valine and leucine/isoleucine, were decreased in partici-
pants consuming TP, although those of aromatic amino acids such
as phenylalanine and tryptophan increased. According to Nie and
Henriksson [47], the metabolism of BCAA increased during
strenuous exercise and the level of alphaketocaproic acid
increased from the transamination of leucine in both muscles and
blood. In addition, serum leucine levels were positively correlated
with serum levels of MDA. Thus, this BCAA change after TP
Fig. 8. Relationship between the changes in major metabolite levels by Pearson's correlation analysis. The changes in lyso-phosphatidylcholine (lysoPC) 16:0 levels were positively
related to those of lysoPC 15:0 (r ¼ 0.90, p < 0.001) and lysoPC 18:0 (r ¼ 0.76, p < 0.001). r, correlation coefﬁcient.
J Ethn Foods 2016; 3: 213e221220consumption may be related to the reduction in insulin resistance
and oxidative stress by improving liver function, and it may be
associated with increased metabolic rates.
3.7. Xanthine metabolism
The present study showed that TP led to a decrease in the levels
of uric acid whereas those of hypoxanthine and xanthine increased.
Serum hypoxanthine levels are associated with exercising, as re-
ported by Syuko et al [48]. The results of the study by Syuko et al
[48] are in accordancewith our results; the participants experienced
a marginal decrease in body weight, percent body fat, and blood TG
levels. A previous study has demonstrated that uric acid causes
mitochondrial oxidative stress that stimulates fat accumulation
independent of excessive caloric intake [49]. Therefore, high levels
of uric acid in blood are associated with the development of obesity
[50] and dyslipidemia [51], besides hypertension [52]. Tsushima
et al [53] also revealed that uric acid production and its levels in
blood were elevated in obesity-induced mice. Thus, increased
levels of hypoxanthine and xanthine with concordant decreased
levels of uric acid in the present study suggest that TP elevated the
metabolic state of subjects with reducing oxidative stress.
The consumption of TP normalizeddyslipidemia and serumMDA
levels in individuals with mild liver dysfunction. These changes
were associated with the serum metabolite patterns; the levels ofLysoPC, LysoPE, and BCAA were decreased in participants after TP
consumption. These metabolic changes by consuming TP repre-
sented the increase of metabolic activities with decreased oxidative
stress, which might be similar to conducting regular exercise.Conﬂicts of interest
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